Cargando…
Why tocilizumab could be an effective treatment for severe COVID-19?
A severe pneumonia-associated respiratory syndrome caused by a new coronavirus was identified in December 2019 (COVID-19), spread rapidly and has become a world-wide public health challenge. About 25% of COVID-19 patients experienced severe complications including acute respiratory distress syndrome...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154566/ https://www.ncbi.nlm.nih.gov/pubmed/32290839 http://dx.doi.org/10.1186/s12967-020-02339-3 |
_version_ | 1783521847626694656 |
---|---|
author | Fu, Binqing Xu, Xiaoling Wei, Haiming |
author_facet | Fu, Binqing Xu, Xiaoling Wei, Haiming |
author_sort | Fu, Binqing |
collection | PubMed |
description | A severe pneumonia-associated respiratory syndrome caused by a new coronavirus was identified in December 2019 (COVID-19), spread rapidly and has become a world-wide public health challenge. About 25% of COVID-19 patients experienced severe complications including acute respiratory distress syndrome (ARDS), and even progressed into an intensive care unit (ICU) admission and died. The exploration for the mortality causes and advancing novel therapeutic development of severe COVID-19 is crucial at the moment. The biopsy samples analysis at autopsy suggested that increased alveolar exudate caused by aberrant host immune response and inflammatory cytokine storm probably impedes alveolar gas exchange and contributes to the high mortality of severe COVID-19 patients. Our research has identified that pathogenic T cells and inflammatory monocytes incite inflammatory storm with large amount of interleukin 6, therefore monoclonal antibody that targets the IL-6 pathways may potentially curb inflammatory storm. Moreover, Tocilizumab treatment that blocking IL-6 receptors showed inspiring clinical results including temperature returned to normal quickly and respiratory function improved. Therefore, we suggest that Tocilizumab is an effective treatment in severe patients of COVID-19 to calm the inflammatory storm and reduce mortality. |
format | Online Article Text |
id | pubmed-7154566 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-71545662020-04-14 Why tocilizumab could be an effective treatment for severe COVID-19? Fu, Binqing Xu, Xiaoling Wei, Haiming J Transl Med Commentary A severe pneumonia-associated respiratory syndrome caused by a new coronavirus was identified in December 2019 (COVID-19), spread rapidly and has become a world-wide public health challenge. About 25% of COVID-19 patients experienced severe complications including acute respiratory distress syndrome (ARDS), and even progressed into an intensive care unit (ICU) admission and died. The exploration for the mortality causes and advancing novel therapeutic development of severe COVID-19 is crucial at the moment. The biopsy samples analysis at autopsy suggested that increased alveolar exudate caused by aberrant host immune response and inflammatory cytokine storm probably impedes alveolar gas exchange and contributes to the high mortality of severe COVID-19 patients. Our research has identified that pathogenic T cells and inflammatory monocytes incite inflammatory storm with large amount of interleukin 6, therefore monoclonal antibody that targets the IL-6 pathways may potentially curb inflammatory storm. Moreover, Tocilizumab treatment that blocking IL-6 receptors showed inspiring clinical results including temperature returned to normal quickly and respiratory function improved. Therefore, we suggest that Tocilizumab is an effective treatment in severe patients of COVID-19 to calm the inflammatory storm and reduce mortality. BioMed Central 2020-04-14 /pmc/articles/PMC7154566/ /pubmed/32290839 http://dx.doi.org/10.1186/s12967-020-02339-3 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Commentary Fu, Binqing Xu, Xiaoling Wei, Haiming Why tocilizumab could be an effective treatment for severe COVID-19? |
title | Why tocilizumab could be an effective treatment for severe COVID-19? |
title_full | Why tocilizumab could be an effective treatment for severe COVID-19? |
title_fullStr | Why tocilizumab could be an effective treatment for severe COVID-19? |
title_full_unstemmed | Why tocilizumab could be an effective treatment for severe COVID-19? |
title_short | Why tocilizumab could be an effective treatment for severe COVID-19? |
title_sort | why tocilizumab could be an effective treatment for severe covid-19? |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154566/ https://www.ncbi.nlm.nih.gov/pubmed/32290839 http://dx.doi.org/10.1186/s12967-020-02339-3 |
work_keys_str_mv | AT fubinqing whytocilizumabcouldbeaneffectivetreatmentforseverecovid19 AT xuxiaoling whytocilizumabcouldbeaneffectivetreatmentforseverecovid19 AT weihaiming whytocilizumabcouldbeaneffectivetreatmentforseverecovid19 |